Straits Times Index
3,306.02 +6.02 (+0.18%) Nikkei
38,596.47 -36.55 (-0.09%) Hang Seng
18,028.52 -306.80 (-1.67%) FTSE 100
8,237.72 -34.74 (-0.42%) Bitcoin USD
64,104.64 -854.66 (-1.32%) CMC Crypto 200
1,329.98 -30.34 (-2.22%)
HROW Jul 2024 16.000 call
| Previous close | 4.5000 |
| Open | 4.2000 |
| Bid | 4.7000 |
| Ask | 7.1000 |
| Strike | 16.00 |
| Expiry date | 2024-07-19 |
| Day's range | 4.2000 - 4.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 131 |
Business WireHarrow Provides TRIESENCE® Relaunch Update
NASHVILLE, Tenn., June 20, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce the successful manufacture of the first of three commercial-scale process performance qualification (PPQ) batches of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is FDA‑approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsiv
Business WireMelt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
NASHVILLE, Tenn., June 06, 2024--Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first patient has been dosed in its Phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non‑IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg). MELT-300 is administered sublingually using Catalent Inc.’s proprietary fast‑dissolving Zy
Business WireHarrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
NASHVILLE, Tenn., June 05, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑2 open-label extension (OLE) clinical study for VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED). ESSENCE-2 OLE was a Phase 3, prospective, multicenter, open-label, clinical study with 202 patients, who had previously completed the ESSENCE‑2 study, re
